alexa Insulin Glargine versus Insulin Detemir: Glycemic Control and Insulin Dose in Type 2 Diabetes Mellitus Patients Using a Medical Record Linkage System in the Netherlands
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Insulin Glargine versus Insulin Detemir: Glycemic Control and Insulin Dose in Type 2 Diabetes Mellitus Patients Using a Medical Record Linkage System in the Netherlands

Ingo A Eland1*, Edith M. Heintjes2, Leanne Houweling2, Ricardo deGrooth3, Thiemo F. Veneman4 and K. Paul Bouter5

1Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands

2PHARMO Institute, Utrecht, The Netherlands

3sanofi-aventis Netherlands B.V., Gouda, The Netherlands

4Department of Internal Medicine, ZGT Hengelo, Hengelo, The Netherlands

5Department of Internal Medicine, Jeroen Bosch Hospital, Den Bosch, The Netherland

*Corresponding Author:
Dr. Ingo Eland
Department of Internal Medicine, St. Antonius Hospital
Po Box. 2500, 3430 EM, Nieuwegein, The Netherlands
Tel: +31 30 6099111
E-mail: [email protected]

Received date October 12, 2011; Accepted date December 22, 2011; Published date December 26, 2011

Citation: Eland IA, Heintjes EM, Houweling L, deGrooth R, Veneman TF, et al. (2011) Insulin Glargine versus Insulin Detemir: Glycemic Control and Insulin Dose in Type 2 Diabetes Mellitus Patients Using a Medical Record Linkage System in the Netherlands. J Diabetes Metab 2:165. doi:10.4172/2155-6156.1000165

Copyright: © 2011 Eland IA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Background: In randomized controlled trials, patients with type 2 diabetes mellitus required higher doses of insulin detemir than insulin glargine to obtain the same glycemic control. However, this may differ in daily clinical practice.

Methods: We conducted a cohort study to compare glycemic control, daily basal insulin dose and persistence in The Netherlands. Data were obtained from the PHARMO record linkage system. Patients starting glargine or detemir in 2004 through 2007 were included if they had a follow-up and history of at least 1 year, including glycated hemoglobin (HbA1c) measurements. Glycemic control and insulin dose were compared within 1 year after start of treatment. Average insulin dose was calculated based on the amount of insulin dispensed overtime.

Results: A total of 708 patients on glargine and 298 on detemir were included. Patients starting glargine had less often used insulin in the previous year (19 versus31%, P<0.001) and less often used oral antihyperglycemic drugs concomitantly (61 versus67%, P<0.05) than those starting detemir. Despite a higher mean HbA1c at baseline in patients who started glargine (8.6% versus8.4%), the change from baseline in HbA1c at follow-up was greater with glargine (–0.9%) than with detemir (–0.4%, P<0.001). The proportion of patients with HbA1c < 7% was similar between the two cohorts. Mean insulin dose at follow-up was significantly lower with glargine than with detemir (31.3 IU versus 36.6 IU, P<0.01).

Conclusions: Patients with type 2 diabetes mellitus who were treated with insulin glargine achieved better glycemic control with lower insulin doses than did patients who were treated with insulin detemir.

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version